Gastrointestinal Stromal Tumors of the Stomach and Esophagus

Surg Clin North Am. 2019 Jun;99(3):543-553. doi: 10.1016/j.suc.2019.02.012.

Abstract

Gastrointestinal stromal tumors (GISTs) arise anywhere along the gastrointestinal tract, most commonly as a result of c-kit or PDGFRA proto-oncogene mutations. Surgical resection is an important component of treatment. However, molecular profiling of GISTs has provided many insights into adjuvant and neoadjuvant therapy options. Imatinib, the most frequently studied medical therapy, has been shown in numerous studies to provide benefit to patients in both the neoadjuvant and adjuvant setting. Interval imaging is an important component of the treatment of GISTs and national surveillance recommendations should be followed.

Keywords: Adjuvant; Esophagus; GIST; Imatinib; Neoadjuvant; Stomach.

Publication types

  • Review

MeSH terms

  • Aftercare / methods
  • Antineoplastic Agents / therapeutic use
  • Catheter Ablation / methods
  • Chemoembolization, Therapeutic / methods
  • Combined Modality Therapy / methods
  • Esophageal Neoplasms / drug therapy
  • Esophageal Neoplasms / pathology
  • Esophageal Neoplasms / surgery*
  • Gastrointestinal Stromal Tumors / drug therapy
  • Gastrointestinal Stromal Tumors / pathology
  • Gastrointestinal Stromal Tumors / surgery*
  • Gene Expression Profiling / methods
  • Humans
  • Imatinib Mesylate / therapeutic use
  • Laparoscopy / methods
  • Neoplasm Metastasis
  • Prognosis
  • Stomach Neoplasms / drug therapy
  • Stomach Neoplasms / pathology
  • Stomach Neoplasms / surgery*
  • Tomography, X-Ray Computed

Substances

  • Antineoplastic Agents
  • Imatinib Mesylate